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OBJECTIVES: To explore the impact of Dupuytren’s Disease (DD) on patients’ qual-
ity of life (QoL) and identify implications for clinical practice. A search of the liter-
ature failed to identify a patient-reported outcome measure for assessing the im-
pact of DD. The study was designed to be the first stage in the development of such
a measure. METHODS: The needs-based model of QoL was adopted and unstruc-
tured qualitative interviews were conducted with DD patients attending out-pa-
tients clinics. Data were transcribed and then underwent interpretative phenom-
enological analysis (IPA) to identify the key impact areas and common themes in
individuals’ personal experiences. RESULTS: Thirty-four DD patients (73.5% male;
aged 41-80; mean (SD): 64.2 (12.5) years) were interviewed. The sample had a wide
range of duration of DD (0.5-40; mean (SD) 12.6 (9.9) years). A total of 953 statements
relating to the impact of DD were identified from the interview transcripts. These
statements fell into 3 major categories of impact; emotional impairment (4 themes
including having no confidence in hand and being embarrassed), activity limita-
tions (10 themes including dressing, gripping and personal care) and QoL (11
themes including avoiding physical contact, self-consciousness and socialisation).
CONCLUSIONS: Dupuytren’s disease impacts on patients in three main areas;
emotional reactions, activity limitations and QoL. In any trial designed to deter-
mine the benefits of new interventions for the disease it is important to ensure that
each of these areas is assessed. It is intended to develop valid and reliable DD-
specific scales to cover each of these outcomes.
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OBJECTIVES: Rheumatoid arthritis (RA) has been associated with significant de-
creases in a patient’s health-related quality of life (HRQL). Our objective was to
measure the HRQL of Greek RA patients treated with adalimumab. These outcomes
were assessed for differences between the results of a generic (EuroQol-5 Dimen-
sion [EQ-5D]) and an RA disease–specific (Health Assessment Questionnaire [HAQ])
instrument. METHODS: Data were drawn from an observational 52-week, single-
arm study that measured the effectiveness of adalimumab in the treatment of
patients with moderate to severe RA. Two instruments were implemented for re-
cording the HRQL during the study duration, the EQ-5D and the HAQ. All statistical
analysis was performed using SPSS software. RESULTS: The outcome measures
revealed that adalimumab is effective in treating patients with moderate to severe
RA. The mean utility score, as indicated by the EQ-5D questionnaire, increased
from 0.433 at baseline to 0.621 after 12 months of treatment. The mean disability
index, as indicated by the HAQ, decreased from 1.341 at baseline to 0.624 at the end
of treatment. Although both instruments reached the same conclusion, there was
only moderate correlation between the instruments (Spearman’s correlation at
baseline and at 12 months, r0.659 and r0.793, respectively). As expected, the
HAQ was more closely correlated with disease activity measures (swollen and
tender joints, visual analog scale [VAS] for pain assessment, and VAS for general
health assessment by both the patient and the physician) than the EQ-5D
questionnaire. CONCLUSIONS: Adalimumab is effective in the treatment of Greek
patients with moderate to severe RA. Caution should be taken in interpreting the
changes in HRQL when different outcome measures are used.
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OBJECTIVES:Determine whether treatments with Unhais da Serra natural mineral
water, a Portuguese spa, are effective in low back pain for spondylarthrosis.
METHODS: A descriptive, longitudinal, observational, uncontrolled prospective
study was conducted. The 51 study participants underwent 14 days of treatment
with Unhais da Serra natural mineral water. Assessment criteria were: pain inten-
sity (Visual Analogue Scale), quality of life (SF36v2), disability (ODIv2), absenteeism,
acute outbreak/relapse, drug consumption. The evaluation was conducted in four
distinct stages: the first day before, 14 days, 3 and 6 months after the thermal
treatment. RESULTS: The mean age of the sample was 60.53 years, 60.8% were
female. The duration of illness was, on average, 7.35 years, 50.9% were retired and
90.2% were from a countryside district. There was a statistically significant im-
provement (p 0.05) in pain intensity, quality of life, disability, absenteeism and
drug consumption, 14 days, 3 and 6 months after thermal treatment compared to
baseline. There was no effect on the number of acute outbreak/relapse. Regarding
socio-demographic and clinical data, we get no consistent results, only low corre-
lations and some differences in just a few moments of assessment.CONCLUSIONS:
This research showed that 14 days of treatment with natural mineral water of
Unhais da Serra spa, reduced pain, disability and drug consumption, improved
quality of life, not influencing the number of outbreaks acute/relapse presented by
the participants. All the beneficial effects were observed in the short and medium
term (six months). No consistent conclusion could be drawn to the possible influ-
ence of socio-demographic and clinical variables. Thus, treatment with Unhais da
Serra spa shows up as an effective complementary treatment modality in selected
patients with lumbar spondylarthrosis. It seems to be justified and useful to famil-
iarize patients and their physicians with this modality of treatment because the
socio-economic impact of the pathology.
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OBJECTIVES: Duloxetine is approved for the treatment of major depressive disor-
der (MDD) and general anxiety disorder (GAD), and for the management of diabetic
peripheral neuropathic pain (DPNP), fibromyalgia (FM), and chronic musculoskel-
etal pain, as studied in patients with osteoarthritis (OA) and chronic low back pain.
This study assessed pain medication use prior to duloxetine initiation among pa-
tients with each of these conditions. METHODS: US administrative claims were
used to identify commercially-insured duloxetine initiators 1/1/2009-3/31/2010
who had any of the 6 medical conditions mentioned above during the 12 months
prior to duloxetine initiation (defined as no duloxetine pill coverage in the previous
90 days). Utilization of pain medications including antidepressants, anticonvul-
sants, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and muscle relax-
ants was assessed over the 3, 6 and 12 months prior to duloxetine initiation.
RESULTS: The study identified 19,546, 5,764, 2,334, 15,362, 12,317, and 27,781 du-
loxetine initiators in the MDD, GAD, DPNP, FM, OA, and low back pain (LBP) groups.
Antidepressant use was high across all conditions over the 12 months prior to
initiation, especially among patients with MDD (84.4%) or GAD (79.9%). Anticonvul-
sant utilization was highest in DPNP (63.1%) and FM (51.9%), lowest in GAD (39.5%),
and similar among other groups (range: 42.8%-48.3%). Opioid use varied greatly
across groups (54.5-81.6%), with the lowest use among GAD patients and the high-
est use among LBP patients. GAD patients had the lowest NSAID use (32.9%), while
OA patients had the highest utilization (58.1%). The use of muscle relaxants ranged
between 29.4% (DPNP) and 56.7% (LBP) at 12 months prior to duloxetine initiation.
Pain medication use in the prior 3 and 6 months showed similar trends.
CONCLUSIONS: Patients used several types of pain medications prior to initiating
duloxetine across disease states. The trends in use were consistent 3, 6, and 12
months prior to duloxetine initiation.
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OBJECTIVES: Osteoporosis represents a significant burden both to patients that
suffers from this condition, given the complications associated with this disease,
as well as to the health care system, given the elevated costs to treat this condi-
tions. Different options are considered in the treatment of osteoporosis, but there
are scanty assessments of this condition in large populations. The objective of this
study is to describe the population patterns of the prevalence of this disease as well
as main treatment trends in primary care centres (PCC) in Madrid. METHODS:
Information was gathered from electronic medical records of PCC of 7 areas of the
region of Madrid. Cross-sectional descriptive study from PCC database. This data-
base contains information about 1,318,020 patients who have visited PCC during
2006 and are older than 25 years-old. Patients with diagnosis of osteoporosis have
been identified. The use of pharmacological interventions (biphosphonate, ralox-
ifene, calcium) are described and compared considering sex, age, weight, height,
comorbidity, concomitant treatments, number of visits to the doctor and other
sociodemographic aspects. RESULTS: Overall, the prevalence of osteoporosis was
4.4%, being women 89.3% of reported cases. The median age was 64 years-old
(interquartile range 73-57). Osteoporotic patients used biphosphonates (33.1%),
raloxifene (3.29%), calcium (40,3%). A 14,3% of patients used only calcium. A 45.31%
of patients did not use calcium or other pharmacological treatments. The median
age of patients who used biphosphonates was 67, whereas the median age of
patients who did not use any treatment, including calcium, was 61. A 7.0% of
patients were referred to the traumatologist. CONCLUSIONS: Different treatment
strategies are considered among physicans of PCC in Spain to manage osteoporotic
patients. A relevant proportion of patients did not use any pharmacological inter-
vention. The treatment strategies used in osteoporosis seem to vary by age, and
should be adapted to individual risk factors.
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OBJECTIVES: Duloxetine is approved to treat major depressive disorder (MDD) and
general anxiety disorder (GAD), and to manage the symptoms of diabetic periph-
eral neuropathic pain (DPNP), fibromyalgia (FM), and chronic musculoskeletal pain
as studied in patients with osteoarthritis (OA) and chronic low back pain. This
study assessed use of pain medications prior to duloxetine initiation among elderly
patients with each of these conditions. METHODS: Duloxetine initiators aged 65
with Medicare Supplemental Insurance in 2007, 2008 and during January 1, 2009-
March 31, 2010 who had any of the 6 medical conditions listed above during the 12
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months prior to duloxetine initiation (defined as no duloxetine pill coverage in the
previous 90 days) were identified via administrative claims. The use of pain related
medications was assessed during the 6 and 12 months prior to duloxetine
initiation.RESULTS:The study identified 1682, 308, 1044, 1363, 4255, and 5189 in the
MDD, GAD, DPNP, FM, OA, and low back pain (LBP) cohorts in 2009-2010. Antide-
pressant use during the 12 months prior to initiation was common, and was high-
est among MDD (87.2%) and GAD patients (83.4%). The use of anticonvulsants was
comparable between cohorts, but highest among patients with DPNP (60.0%) and
FM (54.7%), and between 47.0-52.4% among other cohorts. There was varied use of
opioids across cohorts, ranging from 63.3% (GAD) to 84.7% (LBP). Non-steroidal
anti-inflammatory drugs utilization varied with the lowest use among GAD pa-
tients (30.2%) and the highest among OA patients (45.8%). Utilization of muscle
relaxants widely ranged from 22.0% (DPNP) to 40.4% (FM). Use of pain medication
during the 6 months prior was similar, but was generally 10-15% lower. Use pat-
terns in 2007 and 2008 were similar.CONCLUSIONS:Across disease states, patients
used a variety of medications prior to the initiation of duloxetine. Patterns of use
have largely stayed the same from 2007 through 2010.
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OBJECTIVES: For distribution biologic agents in patients with JIA in Russia, data
about epidemiology, used drugs and their impact on functional status are
necessary. METHODS: Records were examined for 6 months retrospectively. Data
were collected via medical chart review by rheumatologists from 11 regions of
Russia. Functional status was assessed with CHAQ questionnaire. Inclusion crite-
ria: age (younger than 18 years), minimum 6 months since diagnosis of JIA and
availability of 6 months retrospective data. Recruitment: no more than 30% pa-
tients received biologic therapy. Disease-specific criteria: about 50% had oligoar-
thritis, 30-40% - polyarthritis and 10-20% - systemic form. Analysis was performed
with methods of descriptive statistic, parametric and non-parametric criteria.
RESULTS: Data on 405 patients were obtained. Ratio (male:female) was 1:1.6. Av-
erage duration of disease was 5 years. 72% had a disability status caused by JIA. 43%
had mild functional disorders; 32% - moderate; 23% - severe disorders, and only 2%
had no functional disorders. Seventy-two percent patients in subgroup without
functional disorders got biologic therapy, 30% and 28% got biologic agents in sub-
groups with mild and moderate disorders respectively. In subgroup with severe
disorders 41% received biologic therapy; 18% patients with oligoarthritis got bio-
logical agents; 40% - with polyartritis, 54% - with systemic form. CONCLUSIONS:
Prescription of biologic therapy increases in case of more severe form of JIA. Direct
relationship between biologic therapy prescription and functional status was not
revealed.
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OBJECTIVES: Disease-modifying anti-rheumatic drugs (DMARDs) are the corner-
stone of rheumatoid arthritis (RA) pharmacotherapy and should be initiated
promptly after RA diagnosis. We examined trends in DMARD use among RA pa-
tients in Quebec, and factors correlated with DMARD initiation in newly diagnosed
RA. METHODS: Quebec administrative health databases were used to identify RA
subjects and their claims for medical and pharmaceutical services between Janu-
ary 1, 2002 and December 31, 2008. To describe DMARD use, cross-sectional anal-
yses were performed on November 1 of each year. For subjects newly diagnosed
with RA, multivariable logistic regressions were used to identify possible predictors
of DMARD initiation at 12 months and Kaplan-Meier curves to define the probabil-
ity of initiating a DMARD over time. RESULTS: A total of 32,533 subjects were
included (mean age: 67.5 years; 70.4% female). Over the study period, the percent-
age of subjects on a DMARD increased from 42.0% (November 2002) to 43.2% (No-
vember 2008). Being followed by a rheumatologist (vs. GP) was the strongest pre-
dictor of DMARD initiation (OR4.39; 95%CI: 3.80-5.08). The use of NSAIDs,
corticosteroids, and opioids in the year prior to cohort entry and the calendar year
of cohort entry had a positive effect on DMARD initiation, whereas age, comorbidity
score, and the use of acetaminophen had a negative effect. For biologics, calendar
year was the strongest predictor (OR 2007 vs. 200210.78; 95%CI: 2.45-47.37). Of
subjects newly diagnosed in 2002, 0.1% had a biologic initiated within one year,
while for those newly diagnosed in 2007 the percentage was 1.3%. In any newly
diagnosed subjects, averaged over 2002-2007, the probability of having initiated
any DMARDs at 12 months was 38.5% (47.8% for those followed by a
rheumatologist). CONCLUSIONS: Despite encouraging signs for earlier aggressive
RA management, DMARD use appears to be sub-optimal in Quebec. Use of DMARDs
was much higher among subjects followed by a rheumatologist.
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OBJECTIVES: In the last decade, several biological agents (biologics), including anti-
TNFs, have been approved for use in Rheumatoid Arthritis (RA), thus revolutioniz-
ing treatment. Despite the widespread availability of these drugs through Europe,
patient access differs significantly among countries. We aimed to compare the
share of RA patients being treated with biologics in each country and study the
factors that influence the different shares, with focus on the market potential for
Portugal. METHODS: A multivariable linear regression model using SPSS 10.0 was
built to identify which factors best explain a country’s share of prevalent RA pa-
tients treated with biologics. This share was calculated based on IMS Health re-
ported unit sales converted into annualized treatments by applying defined daily
doses by WHO. RESULTS: A total of 21 independent variables were collected for
each of the 15 European countries, including demographic, economic, funding-
related, disease-related and biologics-related data. Model results (Adjusted R2
0,953; SE0,0456) indicated that a country’s share of prevalent RA patients treated
with biologics is mostly explained by its GDP per capita (0.006; p0.0001), the
share of biologics treatments per dispensing channel - hospital vs. Retail
(0.046; p0.149) and the usage of methotrexate (0.26; p0.05). Based on
these variables and their expected evolution we estimated the overall market po-
tential for the Portuguese market, define 4 country clusters and understand Portu-
gal’s relative position among the 15 countries. Share of RA prevalent patients
treated with methotrexate in Portugal may be standing 5 years behind comparable
countries such as UK, France, Germany or Spain, thus impacting the share of pa-
tients treated with biologics. CONCLUSIONS: Portugal presents the lowest share of
RA prevalent patients treated with biologics of all selected countries. Lower GDP
per capita, biologics exclusively dispensed in hospital settings and a low consump-
tion of methotrexate are the best explanatory factors for this reality.
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TREATMENT PATTERNS AMONG PATIENTS WITH SHOULDER OSTEOARTHISTIS
Kozma CM1, Bhattacharyya SK2, Palazola P2
1Research Consultant/Adjunct Professor, University of South Carolina, St. Helena Island, SC,
USA, 2DePuy Mitek, Inc, Raynham, MA, USA
OBJECTIVES: To assess treatment patterns among patients with shoulder osteoar-
thritis (OA).METHODS:Data from Thomson MarketScan, a large national managed
care population, was used to identify patients with a shoulder OA diagnosis in the
first 6 months of 2005 (i.e., the index date). The 360 days post index (identification
period) was used to establish baseline treatments (i.e., conservative management
(pharmaceutical and physical therapy), steroid injections and shoulder surgery).
Patients were required to be continuously eligible for 54 months post-index and
were excluded if they had a shoulder surgery claim in the identification period.
Four cohorts were followed based on the baseline treatments: C1- conservative
treatment; C2- conservative treatment and at least one steroid injection; C3- at
least one steroid injection; C4- no treatment claims. Progression to additional treat-
ments was evaluated descriptively from day 361 to 1260 in 180 increments. Logistic
regression was used to model the odds or having a claim for a treatment. RESULTS:
A total of 3646 patients met the analysis criteria (C1, n2,815(77.2%); C2,
n171(4.7%); C3, n27(0.7%); C4, n633(17.4%)). The distribution was split evenly
between males (50.2%) and females (49.8%). Patients who received steroid injec-
tions in the identification period had the greatest likelihood of having a steroid
injection in the observation period (C1-19.2%;C2-43.9%;C3-44.4%;C4-14.1%). The
percentage with shoulder surgery was 6.4%, 15.2%, 11.1% and 6.5% for C1 to C4,
respectively. Patients with steroids in the observation period (C2 and C3) were more
likely to have surgery in the first year of observation. Logistic regression showed
that females who had steroid injections (C2 and C3 combined) had odds of surgery
that were 2.9 times greater than females with no treatments (C1). CONCLUSIONS:
The most significant predictor of surgery was presence of steroid injections. Rates
of steroid injections and surgery differed based on presence of pre-existing treat-
ments.
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OBJECTIVES: To evaluate the effect of a quality improvement intervention that
provided financial incentives to physicians to encourage adoption of best practices,
coupled with organizational support to improve care management. The interven-
tion, implemented at two pilot sites in Washington State, was aimed at reducing
work disability for patients with occupational injuries or illnesses treated within
the workers’ compensation system. METHODS: At each pilot site, a Center for
Occupational Health and Education (COHE) was established to recruit physicians
for the pilot and to implement the intervention. We conducted a prospective non-
randomized intervention study, with a non-equivalent comparison group, using
difference-in-difference models. The intervention group included patients (31,520)
treated from July 2004 through June 2007 by COHE physicians (n  300). The com-
parison group included patients (40,176) treated by non-COHE physicians practic-
ing in the pilot target areas. The baseline (pre-intervention) period was specified as
July 2001 to June 2003 and included 33,910 patients treated by COHE and non-COHE
physicians. We used logistic regression and generalized linear models to analyze
four outcomes at one year following injury: off work and on disability, disability
days, and disability costs and medical costs per claim. RESULTS: COHE patients
were less likely to be off work and on disability at one year post injury (OR  .79,
P  0.003). The COHE was associated with a statistically significant (p  .01)
reduction in disability days (16.5%) and disability costs (23.7%), and with a non-
signific0ant (p  0.13) reduction of 6.7% in medical costs. Patients treated by
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